BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Summit Therapeutics plc: Block Listing Application

  The block listing application relates to 4,454,158 ordinary shares of one penny each to be issued from time to time in order to satisfy the potential exercise of share options granted under the Company’s 2005 EMI Scheme.

  October 23, 2017

   · 

  1 min read
• Business

  Bruno Lucidi Appointed CEO of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus

  Agenus Chairman and CEO Garo Armen Ph.D. announces the appointment of Bruno Lucidi as CEO of AgenTus Therapeutics.

  October 23, 2017

   · 

  4 min read
• Business

  Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast

  The company will host a live webcast on Monday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results.

  October 23, 2017

   · 

  3 min read
• Biotech Beach

  MannKind Restructures Near-Term Debt Obligations

  MannKind entered into an exchange agreement with the holders of its outstanding 5.75% Convertible Senior Subordinated Exchange Notes due 2018.

  October 23, 2017

   · 

  6 min read
• Pharm Country

  Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

  Immune Pharmaceuticals Inc. announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune.

  October 23, 2017

   · 

  4 min read
• Business

  VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters

  This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec (VB-111), if approved.

  October 23, 2017

   · 

  6 min read
• Biotech Bay

  Soleno Therapeutics Regains Compliance With NASDAQ Listing Requirements

  Soleno is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.

  October 23, 2017

   · 

  2 min read
• Business

  Pixium Vision Establishes an Equity Line Financing With Kepler Cheuvreux

  Pixium Vision announces the implementation of an equity line financing facility with Kepler Cheuvreux.

  October 23, 2017

   · 

  4 min read
• Pharm Country

  ThyroSeq Presented the Results of its Prospective, Double-Blind, Multi-Center International Study Today, at the 87th Annual Meeting of the ATA in Victoria, BC, Canada

  ThyroSeq presented the results of its prospective, double-blind, multi-center international study today, at the 87th Annual Meeting of the ATA in Victoria, BC, Canada.

  October 23, 2017

   · 

  2 min read
• Deals

  Spero Therapeutics Launches Initial Public Offering

  Spero has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock.

  October 23, 2017

   · 

  3 min read